17.56
price up icon2.09%   0.36
 
loading
전일 마감가:
$17.20
열려 있는:
$17.2
하루 거래량:
11,609
Relative Volume:
0.18
시가총액:
$929.11M
수익:
-
순이익/손실:
$-143.59M
주가수익비율:
-6.219
EPS:
-2.8236
순현금흐름:
$-119.47M
1주 성능:
+5.53%
1개월 성능:
+9.82%
6개월 성능:
-6.74%
1년 성능:
-10.13%
1일 변동 폭
Value
$16.78
$17.58
1주일 범위
Value
$16.78
$18.00
52주 변동 폭
Value
$11.51
$25.50

Pharvaris Nv Stock (PHVS) Company Profile

Name
명칭
Pharvaris Nv
Name
전화
-
Name
주소
-
Name
직원
119
Name
트위터
Name
다음 수익 날짜
2024-08-05
Name
최신 SEC 제출 서류
Name
PHVS's Discussions on Twitter

PHVS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
PHVS
Pharvaris Nv
17.56 929.11M 0 -143.59M -119.47M -2.8236
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
445.82 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
520.29 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
321.94 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.53 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
267.12 28.51B 3.81B -644.79M -669.77M -6.24

Pharvaris Nv Stock (PHVS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-06-11 개시 Guggenheim Buy
2025-04-29 개시 Cantor Fitzgerald Overweight
2023-09-25 개시 Wedbush Outperform
2023-08-15 업그레이드 Morgan Stanley Equal-Weight → Overweight
2022-10-05 개시 Bryan Garnier Buy
2022-09-13 재개 JMP Securities Mkt Outperform
2022-08-23 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2022-08-22 다운그레이드 BofA Securities Neutral → Underperform
2022-05-25 개시 JMP Securities Mkt Outperform
2021-03-02 개시 BofA Securities Neutral
2021-03-02 개시 Morgan Stanley Overweight
2021-03-02 개시 Oppenheimer Outperform
2021-03-02 개시 SVB Leerink Outperform
모두보기

Pharvaris Nv 주식(PHVS)의 최신 뉴스

pulisher
Jun 16, 2025

(PHVS) Trading Advice - news.stocktradersdaily.com

Jun 16, 2025
pulisher
Jun 16, 2025

Pharvaris presents new data on oral angioedema treatment at EAACI By Investing.com - Investing.com UK

Jun 16, 2025
pulisher
Jun 16, 2025

Clinical Trial Results: Revolutionary Oral HAE Drug Prevents Attacks and Improves Quality of Life in 97.8% of Patients - Stock Titan

Jun 16, 2025
pulisher
Jun 14, 2025

Analysts Set Pharvaris (NASDAQ:PHVS) Price Target at $36.20 - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim - Defense World

Jun 12, 2025
pulisher
Jun 12, 2025

Cantor Fitzgerald Weighs in on Pharvaris FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Pharvaris (PHVS) Gains Buy Rating with Promising Market Potentia - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Bank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Guggenheim Initiates Coverage on Pharvaris With Buy Rating, $32 Price Target - marketscreener.com

Jun 11, 2025
pulisher
Jun 11, 2025

Pharvaris (PHVS) Receives New Buy Rating and $32 Target from Gug - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Millennium Management LLC Trims Stake in Pharvaris (NASDAQ:PHVS) - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Pharvaris Schedules Key Shareholder Meeting: What HAE Treatment Investors Should Know - Stock Titan

Jun 10, 2025
pulisher
Jun 10, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS) - Defense World

Jun 10, 2025
pulisher
Jun 09, 2025

What is Leerink Partnrs’ Forecast for Pharvaris Q2 Earnings? - Defense World

Jun 09, 2025
pulisher
Jun 07, 2025

Pharvaris (NASDAQ:PHVS) Given “Outperform” Rating at Wedbush - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush | PHVS Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wed - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Citizens JMP reiterates Market Outperform rating for Pharvaris stock By Investing.com - Investing.com UK

Jun 05, 2025
pulisher
Jun 04, 2025

Transcript : Pharvaris N.V.Special Call - marketscreener.com

Jun 04, 2025
pulisher
Jun 02, 2025

Pharvaris (PHVS) Spotlights Promising Deucrictibant Data at Key Workshop | PHVS Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Pharvaris reports promising results for deucrictibant in HAE By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 01, 2025

Pharvaris (NASDAQ:PHVS) Shares Acquired by Deutsche Bank AG - Defense World

Jun 01, 2025
pulisher
May 27, 2025

Northern Trust Corp Purchases 76,188 Shares of Pharvaris (NASDAQ:PHVS) - Defense World

May 27, 2025
pulisher
May 24, 2025

How To Trade (PHVS) - news.stocktradersdaily.com

May 24, 2025
pulisher
May 20, 2025

Cubist Systematic Strategies LLC Purchases New Holdings in Pharvaris (NASDAQ:PHVS) - Defense World

May 20, 2025
pulisher
May 19, 2025

New Clinical Data Reveals Long-Term Success of Oral HAE Treatment Deucrictibant - Stock Titan

May 19, 2025
pulisher
May 18, 2025

Pharvaris (NASDAQ:PHVS) Shares Gap Down – Here’s What Happened - Defense World

May 18, 2025
pulisher
May 18, 2025

Brokers Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 18, 2025
pulisher
May 17, 2025

Q2 Earnings Forecast for Pharvaris Issued By Leerink Partnrs - Defense World

May 17, 2025
pulisher
May 17, 2025

Cantor Fitzgerald Cuts Pharvaris (NASDAQ:PHVS) Price Target to $25.00 - Defense World

May 17, 2025
pulisher
May 17, 2025

Research Analysts Issue Forecasts for Pharvaris Q2 Earnings - Defense World

May 17, 2025
pulisher
May 16, 2025

Pharvaris (NASDAQ:PHVS) Holdings Decreased by Barclays PLC - Defense World

May 16, 2025
pulisher
May 15, 2025

The Manufacturers Life Insurance Company Reduces Stake in Pharvaris (NASDAQ:PHVS) - Defense World

May 15, 2025
pulisher
May 15, 2025

Pharvaris (NASDAQ:PHVS) Shares Down 5.1% on Disappointing Earnings - Defense World

May 15, 2025
pulisher
May 14, 2025

Transcript : Pharvaris N.V. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

PHVS Reports Decrease in Cash Reserves by March Quarter End | PH - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Pharvaris (PHVS) Target Price Revised by Cantor Fitzgerald | PHV - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Pharvaris (PHVS) Target Price Increased by Wedbush Amid Clinical Progress | PHVS Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Wedbush Adjusts Pharvaris Price Target to $17 From $25, Maintains Outperform Rating - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

(PHVS) Long Term Investment Analysis - news.stocktradersdaily.com

May 14, 2025
pulisher
May 13, 2025

Pharvaris Reports First Quarter 2025 Financial Results and Provides Business Update - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Pharvaris Hits Major FDA Milestone for HAE Drug Pipeline While Phase 3 Trials Show Strong Progress - Stock Titan

May 13, 2025
pulisher
May 13, 2025

Pharvaris (PHVS) Expected to Announce Earnings on Wednesday - Defense World

May 13, 2025
pulisher
May 12, 2025

Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4 - Stock Titan

May 12, 2025
pulisher
May 07, 2025

Pharvaris (NASDAQ:PHVS) Shares Acquired by JPMorgan Chase & Co. - Defense World

May 07, 2025
pulisher
May 03, 2025

When (PHVS) Moves Investors should Listen - news.stocktradersdaily.com

May 03, 2025
pulisher
May 02, 2025

Pharvaris NV expected to post a loss of 76 cents a shareEarnings Preview - TradingView

May 02, 2025
pulisher
May 02, 2025

Geode Capital Management LLC Has $735,000 Stock Position in Pharvaris (NASDAQ:PHVS) - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Holdings Increased by Legal & General Group Plc - Defense World

May 02, 2025
pulisher
May 02, 2025

Analysts Offer Predictions for Pharvaris FY2025 Earnings - Defense World

May 02, 2025
pulisher
May 02, 2025

Pharvaris (NASDAQ:PHVS) Research Coverage Started at Cantor Fitzgerald - Defense World

May 02, 2025

Pharvaris Nv (PHVS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$20.52
price down icon 1.06%
$35.91
price down icon 0.64%
$21.27
price up icon 1.67%
$104.85
price down icon 0.99%
$104.80
price down icon 0.28%
biotechnology ONC
$267.12
price up icon 0.12%
자본화:     |  볼륨(24시간):